2025Year7Month8Day,Global medical technology giant Medtronic (NYSE: MDT) Announced,AppointmentChad SpoonerFor its diabetes business unitMiniMedChief Financial Officer (CFO), since7Month14Effective from the date.This appointment comes as Medtronic plans to spin off its diabetes business into an independent publicly traded company.SpoonerWill be responsible for building the financial system of the new entity to support its strategic transformation and long-term growth objectives.

Chad SpoonerWith over25Years of financial management experience in healthcare, consumer, and industrial sectors.Before joining Medtronic, he served as a global consumer goods public companyBICThe chief financial officer has led several strategic transformation and cost optimization projects. His career began at General Electric (GE), gradually advancing to the core management level in the fields of auditing and financial planning. Subsequently, he has worked atRaffaela Apparel Group、Slingshot HealthSuch as MedtronicCFO, and concurrently serves as a private equity firmTenex Capital ManagementSenior Operations Finance Role, Skilled in Driving Corporate Growth through Capital Operations.

"I am delighted to be involved in shaping the future of a company with a mission to improve the lives of people with diabetes."SpoonerSaid, "Look forward to working withQue Dallara(Elect)MiniMed"CEO) and the team jointly build an agile and innovative financial organization to create long-term value for shareholders and patients."

Executive Vice President of Medtronic's Diabetes Business and IncomingMiniMedChief Executive OfficerQue DallaraEmphasized: "At the critical juncture of business transformation,ChadThe addition reflects our commitment to long-term success. His deep financial expertise and cross-industry transformation experience will be a great asset.MiniMedBuild a solid financial foundation to address the challenges and opportunities after independent operation."

According to public information,SpoonerThe responsibilities will cover financial strategy planning, capital allocation optimization, and support for profitable growth. Particularly during the spin-off transition period, it is necessary to ensure business continuity and enhance shareholder returns.Medtronic did not disclose the specific terms of its remuneration, but industry analysts pointed out that the compound annual growth rate of the diabetes device market exceeds8%，MiniMedIndependent operation or unlock greater valuation potential.

Medtronic this year5Announced in the month, it plans to spin off its diabetes business into an independent company "MiniMed", aiming to create a "more focused Medtronic" by streamlining the product portfolio, while incubating a scaled, independent leader in the diabetes field. After the split,MiniMedWill focus on insulin pumps, continuous glucose monitoring systems (CGM), and other core products, strengthening competitiveness in the diabetes management market.

This spin-off is Medtronic"Continuation of the 'Simplify Operations, Focus on High-Growth Areas' Strategy."In recent years, its diabetes business has faced competition from Abbott,Dexcometc.CGMIntense competition among manufacturers, after becoming independent,MiniMedIt is expected to accelerate product iteration through a more flexible decision-making mechanism, such as a closed-loop insulin delivery system integrated with artificial intelligence algorithms.

Market Research InstitutionGlobalDataAnalysis shows that the global diabetes management device market size is expected2030Yearly Reach580billion dollars, and financial robustness will become the key for enterprises to seize market share.SpoonerThe appointment is seen as Medtronic strengtheningMiniMedAn important signal of financial independence, whether it can achieve dual breakthroughs in profit growth and technological innovation after the spin-off？Instrument之家 will continue to follow up.